Journals / Marmara Pharmaceutical Journal / 2017 / Cilt: 21 - Sayı: 1

Aterosklerozun Patofizyolojisi ve Risk Faktörleri

Pages
1–9
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, lipoproteins that are considered to contribute formation of the pathogenesis of atherosclerosis by creating foam cells were examined and it is aimed to evaluate this phenomenon considering the many parameters joining it.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:atherosclerosis and its complications is the leading cause of death both in our country and in the world. atherosclerosis is a disease that affects the intima layers of medium and large arteries with its typical lesions “atherosclerotic plaques”. endothelial dysfunction is one of the basic mechanisms in the atherosclerotic process.
📊
Key Findings & Data:Classic and newly identified risk factors leading to a decrease in the vasodilator response creates chronic injury.
💡
Conclusion & Impact:In this study, lipoproteins that are considered to contribute formation of the pathogenesis of atherosclerosis by creating foam cells were examined and it is aimed to evaluate this phenomenon considering the many parameters joining it.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

atherosclerosis and its complications is the leading cause of death both in our country and in the world. atherosclerosis is a disease that affects the intima layers of medium and large arteries with its typical lesions “atherosclerotic plaques”. endothelial dysfunction is one of the basic mechanisms in the atherosclerotic process. Classic and newly identified risk factors leading to a decrease in the vasodilator response creates chronic injury. Thus, vasoconstriction composed in endothelium, accumulation of inflammatory cells, smooth muscle cell migration, cytokine production cause the increase of events such as the formation of atherosclerotic plaques. endothelial dysfunction is not only the first step of the atherosclerotic plaque formation process, but also cause triggering of atherogenic events cracking and the growth of plaque. The most important factor that plays a role in the pathogenesis of atherosclerosis is hypercholesterolemia. epidemiological studies indicate that along many genetic and environmental factors, increased serum cholesterol levels is enough alone for development of atherosclerosis in the absence of other known risk factors. In this study, lipoproteins that are considered to contribute formation of the pathogenesis of atherosclerosis by creating foam cells were examined and it is aimed to evaluate this phenomenon considering the many parameters joining it.

Özet

Dünyada ve ülkemizde ateroskleroz ve komplikasyonları en önde gelen ölüm nedenidir. ateroskleroz, tipik lezyonu ateroma plakları olan orta ve büyük çaplı arterlerin intima tabakalarını etkileyen bir hastalıktır. endotel disfonksiyonu aterosklerotik süreçteki temel mekanizmalardan biridir. klasik ve yeni belirlenen risk faktörleri endotelde vazodilatatör cevabın azalmasına yol açan kronik hasarlanma oluştururlar. Böylece endotelde oluşan vazokonstriksiyon, inflamatuvar hücrelerin birikimi, düz kas hücrelerinin migrasyonu, sitokin üretiminin artışı gibi olaylar aterosklerotik plak oluşumuna neden olurlar. endotel disfonksiyonu yalnız plak oluşumuna neden olan aterosklerotik sürecin ilk basamağı olmakla kalmaz, ayrıca oluşan plağın büyümesine, çatlamasına ve trombojenik olayların tetiklenmesine de neden olur. Hiperkolesterolemi; ateroskleroz patogenezinde rol oynayan en önemli faktördür. epidemiyoloji çalışmaları, pek çok genetik ve çevresel faktör arasında artmış serum kolesterol düzeylerinin, diğer bilinen risk faktörlerinin yokluğunda bile ateroskleroz gelişimine tek başına yeterli olduğunu göstermektedir. Bu çalışmada köpük hücrelerin oluşumunu sağlayarak ateroskleroz patogenezine katkısı bulunduğu düşünülen lipoproteinler incelenirken, bu fenomene katıldığı düşünülen pek çok parametrenin de ele alınarak değerlendirilmesi amaçlanmıştır.

🔖

Cite This Article

TANRIVERDİ, B., TETİK, Ş. S. (2017). Aterosklerozun Patofizyolojisi ve Risk Faktörleri. Marmara Pharmaceutical Journal, Cilt: 21 - Sayı: 1, 1–9. https://ajindex.com/articles/283693

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Faller Dv. endothelial cell responses to hypoxic stress. Clin exp Pharmacol Physiol 1999; 26: 74-84. Carlson JT, rangemark C, Hedner Ja. attenuated endothelium dependent vascular relaxation in patients with sleep apnea. J Hypertens 1996; 14: 577-84. Tetik Ş, ak k. kardiyovasküler hastalıklarda trombosit fonksiyon testleri: patofizyolojiden klinik yaklaşıma. Cumhuriyet Med J 2010; 32: 264-74.
  2. Chen C, Halkos Me, Surowiec SM, Conklin BS, Lin PH, Lumsden aB. effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg res 2000;88:26-33. klein I, Ojamaa k. Thyroid hormone and the cardiovascular system. n engl J Med 2001;344:501-9.
  3. Toft aD, Boon na. Thyroid disease and the heart. Heart 2000;84:455-60.
  4. Yuvanç U, Çiçek D, Yeşilbursa D, karaağaç k, Şentürk T, Siğirli D, Jordan J. akut miyokard infarktüsünde ortalama trombosit hacminin bir yıllık mortalite ve revaskülarizasyon ihtiyacı üzerine etkisi. Mn-kardiyoloji Derg 2004;11:416-20.
  5. Wallentin L, Lindahl B, Siegbahn a. Unstable angina and non ST-elevation MI. In: Cardiology, 1st ed. editors: Crawford MH, DiMarco JP, Paulus WJUSa. elsevier Science Limited. 2001. Tetik Ş, ak k, Yardımcı kT. Trombosit fonksiyon testlerini etkileyen faktörler. Cumhuriyet Med J 2012; 34:123-7.
  6. Sokolow M, Mcilory Me. Clinical cardiology, second edition. WB Saunders Com., new York. 1979, pp 124. Helgeland a, Hjermann I, Leren P, enger S, Holme I. HDL cholesterol and antihypertensive drugs: the Oslo Study. Br Med J 1978;2:403. Third report of the national Cholesterol education Program (nCeP) expert Panel on Detection, evaluation, and Treatment of High Blood Cholesterol in adults (adult Treatment Panel III) final report. Circulation 2002;106:3143-421. roger vL, Go aS, Lloyd-Jones DM, Benjamin eJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford eS, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit Ja, Howard vJ, kissela BM, kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli a, Matchar DB, Moy CS, Mozaffarian D, Mussolino Me, nichol G, Paynter nP, Soliman eZ, Sorlie PD, Sotoodehnia n, Turan Tn, virani SS, Wong nD, Woo D, Turner MB; american Heart association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2012 update: a report from the american Heart association. Circulation 2012;125:188-97. erratum in Circulation 2012;125:e1001. assmann, G. Dabetic Dyslipidaemia results From the Prospective Cardiovascul